RUNX1 and breast cancer: Moreover, BC patients with a history of TKI treatment were more likely to harbour −7/del(7p), −9/del(9p), and complex CNAs than those without TKI treatment, while BCOR, TP53, and RUNX1 mutations were less frequent in TKI-treated patients.